Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Physicians who Implant Taxus Stents

Goran Olivecrona, MD, PhD., Consulting Cardiologist
Goran Olivecrona, MD, PhD., Consulting Cardiologist
University of Lund
December 15, 2008
Are all statins equal ?
Analysis of: Patients Taking Lipitor Had a Significantly Reduced Risk of Cardiovascular Events Compared with Patients Taking Simvastatin, New Observational Study Shows (pharmalive.com)
Retrospective studies should be viewed with caution. Most retrospective studies which may contain a bias in the prescribed treatment should be anlysed with matched propencity score. To confirm the results a randomized trial would essentially be needed.
Giuseppe Biondi-Zoccai, MD, Assistant Professor of Cardiology
Giuseppe Biondi-Zoccai, MD, Assistant Professor of Cardiology
University of Turin
Analysis of: Generic Heart Drugs as Good as Brand-Name Counterparts (www.washingtonpost.com)
Generic drugs are cheaper equivalent of brand-name (aka proprietary) drugs which become available after a specific drug patent expires. There is ongoing debate whether generic drugs are as safe and as effective as their brand-name counterparts. Recent evidence from a comprehensive review published in...
Analysis of: Medtronic Endeavor Heart Stent Tied to Complications (www.bloomberg.com)
The Endeavour stent appears to have a higher restenosis rate than currently marketed Drug Eluting Stents without the improved safety profile claimed by the company.  This finding is at odds with the companies marketing message to cardiologists.  These studies, along with the introduction of...
Giuseppe Biondi-Zoccai, MD, Assistant Professor of Cardiology
Giuseppe Biondi-Zoccai, MD, Assistant Professor of Cardiology
University of Turin
Analysis of: Metabolic Syndrome Not Useful in Predicting Cardiovascular Risk (www.medpagetoday.com)
Metabolic syndrome is a cluster of individual characteristics that has been preliminarily associated with adverse events such as heart attack and stroke If proved an independent cause of cardiovascular disease, metabolic. syndrome could become another feasible target of pharmacologic primary prevention,...
Analysis of: Medtronic Says Thrombus Aspiration Before Stenting Betters Survival Rates Of Myocardial Infarction Patients (www.rttnews.com)
Mechanical thrombectomy of the coronary arteries has becoming increasingly more common with the advent of simpler aspiration catheters.  Although its use in the setting of acute myocardial infarction is even more common, it is not routine.  Randomized data indicating its effect on clinical...
Analysis of: New data show Tekturna HCT® is twice as effective at reducing blood pressure than the diuretic HCT alone (www.novartis.com)
It is well known that the addition of thiazide diuretic to ACEI or ARB treatment adds about 10 mm Hg reduction on top of the 10 mm Hg reduction provided by the ACEI or ARB agent.  It is expected that blocking renin in the renin angiotensin system with Tekturna would provide a similar result.
Analysis of: Great Drug, but Does It Prolong Life? (www.nytimes.com)
Statin therapy in lower risk populations will not have as profound an effect as in high risk subsets but still very likely has overall positive benefits.
Forrest Rubenstein, MD, Cardiac, Thoracic and Vascular Surgeon
Rubenstein Cardiovascular and Thoracic Surgery
Analysis of: Pinning Down Mortality Rates After Bariatric Surgery (www.medscape.com)
 Bariatric surgery is a major operative procedure that caries significant morbidity and mortality risks due to the comorbid diseases seen in this patient population.  This procedure is increasing in frequency as more patients are willing to have it and more surgeons are becoming proficient. The...
Analysis of: Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration (www.pipelinereview.com)
TRITON-TIMI 38 study of 13,608 patients with ACS compared prasugrel against clopidogrel, combined with aspirin.  Prasugrel reduced the combined rate of CV death, MI or stroke (12.1% for clopidogrel vs. 9.9% for prasugrel). The benefit came at a cost of increased serious bleeding (1.4%, vs....
Samuel Butman, MD, Interventional Cardiologist
Samuel Butman, MD, Interventional Cardiologist
Verde Valley Heart LLC
Analysis of: Schering releases ENHANCE data today (www.tradingmarkets.com)
The reality that the actual details of the ENHANCE have not been circulated and that alternate explanations or caveats may be raised is probably unimportant.   The bottom line carries the day and the bottom line is that the trial's title, ENHANCE, was not achieved by the addition of VYTORIN when...

Page : 1 2 3 4 5 6 7 8 9 10 Next1 to 10 of 112

Analytics


Generated at 2009-01-07T07:00:32.297